Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia. The company said it doesn’t intend ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

NUPLAZID (pimavanserin), Acadia’s treatment for Parkinson’s disease psychosis, delivered $168.5 million in Q2 2025 sales, representing a 7% increase year-over-year.

Nuplazid (pimavanserin) is already FDA-approved to treat psychosis caused by Parkinson's disease, but Acadia's hope to expanding that use to the Alzheimer's population were shot down by a complete ...

Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In ...

NUPLAZID (pimavanserin), Acadia’s treatment for Parkinson’s disease psychosis, delivered $168.5 million in Q2 2025 sales, representing a 7% increase year-over-year. The product showed strong ...